Current Status of Gene Therapy for Lung Cancer and Head and Neck Cancer

Clinical Cancer Research

Volumn 9, Issue 14, 2003, Pages 5055-5067

  Moon, Chulso ^b   Oh, Yun ^a   Roth, Jack A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; PROTEIN P53;

APOPTOSIS; BYSTANDER EFFECT; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; FEVER; FLU LIKE SYNDROME; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE REPLACEMENT THERAPY; GENE THERAPY; GENETIC TRANSDUCTION; HEAD AND NECK CANCER; HUMAN; HYPERBILIRUBINEMIA; INJECTION PAIN; LIVER CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; REVIEW; SEPSIS; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS;

EID: 0242694530     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Verma, I., and Somia, N. Gene therapy: promises, problems and prospects. Nature (Lond.), 389: 239-242, 1997.
2. Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., Hong, W. K., Komaki, R., Lee, J. J., Nesbitt, J. C., Pisters, K. M., Putnam, J. B., Schea, R., Shin, D. M., Walsh, G. L., Dolormente, M. M., Han, C. I., Martin, F. D., Yen, N., Xu, K., Stephens, L. C., McDonnell, T. J., Mukhopadhyay, Y., and Cai, D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med., 2: 985-991, 1996.
3. Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., Katz, D., Blaese, R. M., and Oldfield, E. H. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med., 3: 1354-1361, 1997.
4. Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J. C., Hodi, F. S., Liebster, L., Lam, P., Mentzer, S., Singer, S., Tanabe, K. K., Cosimi, A. B., Duda, R., Sober, A., Bhan, A., Daley, J., Neuberg, D., Parry, G., Rokovich, J., Richards, L., Drayer, J., Berns, A., Clift, S., Cohen, L. K., Mulligan, R. C., and Dranoff, G. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA, 95: 13141-13146, 1998.
5. Palu, G., Cavaggioni, A., Calvi, P., Franchin, E., Pizzato, M., Boschetto, R., Parolin, C., Chilosi, M., Ferrini, S., Zanusso, A., and Colombo, F. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther., 6: 330-337, 1999.
6. Peng, K-W., and Vile, R. Vector development for cancer gene therapy. Tumor Targeting, 4: 3-11, 1999.
7. Ramesh, R., Saeki, T., Templeton, N. S., Ji, L., Stephens, L. C., Ito, I., Wilson, D. R., Wu, Z., Branch, C. D., Minna, J. D., and Roth, J. A. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol. Ther., 3: 337-350, 2001.
8. Plautz, G. E., Yang, Z. Y., Wu, B. Y., Gao, X., Huang, L., and Nabel, G. J. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. USA, 90: 4645-4649, 1993.
9. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. Onyx-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3: 639-645, 1997.
10. Moolten, F. L. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther., 1: 279-287, 1994.
11. Peng, K. W., Vile, R. G., Cosset, F. L., and Russell, S. J. Selective transduction of protease rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther., 6, 1552-1557, 1999.
12. Haisma, H. J., Pinedo, H. M., Rijswijk, A., der Meulen-Muileman, I., Sosnowski, B. A., Ying, W., Beusechem, V. W., Tillman, B. W., Gerritsen, W. R., and Curiel, D. T. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther., 6: 1469-1474, 1999.
13. Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Medina, O. P., Heikkila, P., Kantor, C., Gahmberg, C. G., Salo, T., Konttinen, Y. T., Sorsa, T., Ruoslahti, E., and Pasqualini, R. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol., 17: 768-774, 1999.
14. Miller, N., and Whelan, J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum. Gene Ther., 8: 803-815, 1997.
15. Freeman, S. M., Ramesh, R., and Marrogi, A. J. Immune system in suicide gene therapy. Lancet, 349: 2-3, 1997.
16. Vile, R. G., Castleden, S., Marshall, J., Camplejohn, R., Upton, C., and Chong, H. Generation of an anti-tumor immune response in a non-immunogenic tumor: HSVtk-killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoral cytokine expression. Int. J. Cancer, 71: 267-274, 1997.
17. Bouvet, M., Ellis, L. M., Nishizaki, M., Fujiwara, T., Liu, W., Bucana, C. D., Fang, B., Lee, J. J., and Roth, J. A. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res., 58: 2288-2292, 1998.
18. Liu, Y., Thor, A., Shtivelman, E., Cao, Y., Tu, G., Heath, T. D., and Debs, R. J. Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J. Biol. Chem., 274: 13338-13344, 1999.
19. Frank, D. K., Frederick, M. J., Liu, T. J., and Clayman, G. L. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. Clin. Cancer Res., 4: 2521-2528, 1998.
20. Touraine, R. L., Ishii-Morita, H., Ramsey, W. J., and Blaese, R. M. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther., 5: 1705-1711, 1998.
21. Colombo, M. P., Modesti, A., Parmiani, G., and Forni, G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res., 52: 4853-4857, 1992.
22. Ram Melcher, A., Todryk, S., Hardwick, N., Ford, M., Jacobson, M., and Vile, R. G. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med., 4: 581-587, 1998.
23. Castleden, S. A., Chong, H., Garcia-Ribas, I., Melcher, A. A., Hutchinson, G., Roberts, B., Hart, I. R., and Vile, R. G. A family of bicistronic vectors to enhance both local and systemic anti-tumor effects of HSVtk or cytokine expression in a murine melanoma model. Hum. Gene Ther., 8: 2087-2102, 1997.
24. Mullen, C. A., Coale, M. M., Lowe, R., and Blaese, R. M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res., 54: 1503-1506, 1994.
25. Culver, K. W., and Blaese, R. M. Gene therapy for cancer. Trends Genet., 10: 174-178, 1994.
26. Roth, J. A., and Cristiano, R. J. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. (Bethesda), 89: 21-39, 1997.
27. Kokoris, M. S., Sabo, P., Adman, E. T., and Black, M. E. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther., 6: 1415-1426, 1999.
28. Taniguchi, T., Rigg, A., and Lemoine, N. R. Targeting angiogenesis: genetic intervention which strikes at the weak link of tumorigenesis. Gene Ther., 5: 1011-1013, 1998.
29. Li, H., Lu, H., Griscelli, F., Opolon, P., Sun, L. Q., Ragot, T., Legrand, Y., Belin, D., Soria, J., Soria, C., Perricaudet, M., and Yeh, P. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther., 5: 1105-1113, 1998.
30. Blezinger, P., Wang, J., Gondo, M., Quezada, A., Mehrens, D., French, M., Singhal, A., Sullivan, S., Rolland, A., Ralston, R., and Min, W. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat. Biotechnol., 17: 343-348, 1999.
31. Cao, Y., O'Reilly, M. S., Marshall, B., Flynn, E., Ji, R. W., and Folkman, J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases, J. Clin. Investig., 101: 1055-1063, 1998.
32. Marte, B. M., and Downward, J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci., 22: 355-358, 1997.
33. Todryk, S., McLean, C., Ali, S., Entwistle, C., Boursnell, M., Rees, R., and Vile, R. Disabled infectious single-cycle herpes simplex virus vector for immunotherapy of colorectal cancer. Hum. Gene Ther., 10: 2757-2768, 1999.
34. Pardoll, D. M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol., 13: 399-415, 1995.
35. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., Deleo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med., 1: 1297-1302, 1995.
36. Albert, M. L., Sauter, B., and Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restriected CTLs. Nature (Lond.), 392: 86-89, 1998.
37. Wang, R. F., Wang, X., Atwood, A. C., Topalian, S. L., and Rosenberg, S. A. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science (Wash. DC), 284: 1351-1354, 1999.
38. Wang, R. F., Wang, X., and Rosenberg, S. A. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells. J. Exp. Med., 189: 1659-1668, 1999.
39. Boon, T., and Van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 183: 725-729, 1996.
40. Pardoll, D. M. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA, 96: 5340-5342, 1999.
41. Parmiani, G. Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol. Today, 14: 536-538, 1993.
42. Houghton, A. N. Cancer antigens: immune recognition of self and altered self. J. Exp. Med., 180: 1-4, 1994.
43. Banchereau, J., and Steinman, R. M. Dendritic cells and the control of immunity. Nature (Lond.), 392: 245-252, 1998.
44. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow derived cells in presenting MHC class I-restricted tumor antigens. Science (Wash. DC), 264: 961-965, 1994.
45. Vile, R. G., and Chong, H. Immunotherapy: combinatorial molecular immunotherapy-a synthesis and suggestions. Cancer Metastasis Rev., 15: 351-364, 1996.
46. Melcher, A. A., Gough, M. J., Todryk, S., and Vile, R. G. Apoptosis or necrosis for tumor immunotherapy: what's in a name? J. Mol. Med., 77: 824-833, 1999.
47. Melcher, A., Todryk, S., Bateman, A., Chong, H., Lemoine, N. R., and Vile, R. G. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Cancer Res., 59: 2802-2805, 1999.
48. Overwijk, W. W., Lee, D. S., Surman, D. R., Irvine, K. R., Touloukian, C. E., Chan, C. C., Carroll, M. W., Moss, B., Rosenberg, S. A., and Restifo, N. P. Vaccination with a recombinant vaccinia virus encoding a self antigen induced autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4+ T lymphocytes. Proc. Natl. Acad. Sci. USA, 96: 2982-2987, 1999.
49. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767, 1990.
50. Rygaard, K., Vindelov, L. L., and Speng Thomsen, M. Expression of myc family oncoproteins in small-cell lung-cancer cell lines and xenografts. Int. J. Cancer, 54: 144-152, 1993.
51. Takahashi, T., Obata, Y., Sekido, Y., Hida, T., Ueda, R., Watanabe, H., Ariyoshi, Y., Sugiura, T., and Takahashi, T. Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. Cancer Res., 49: 2683-2688, 1989.
52. Barr, L. F., Campbell, S. E., and Baylin, S. B. Protein kinase C-β 2 inhibits cycling and decreases c-myc-induced apoptosis in small cell lung cancer cells. Cell Growth Differ., 8: 381-392, 1997.
53. Kumagai, T., Tanio, Y., Osaki, T., Hosoe, S., Tachibana, I., Ueno, K., Kijima, T., Horai, T., and Kishimoto, T. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements. Cancer Res., 56: 354-358, 1996.
54. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
55. 1 checkpoint control. Cell, 82: 675-684, 1995.
56. Nguyen, D. M., Wiehle, S. A., Koch, P. E., Branch, C., Yen, N., Roth, J. A., and Cristiano, R. J. Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex. Cancer Gene Ther., 4: 191-198, 1997.
57. Hamada, K., Alemany, R., Zhang, W. W. Hittelman, W. N., Lotan, R., Roth, J. A., and Mitchell, M. F. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res., 56: 3047-3054, 1996.
58. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Cai, D. W., Owen Schaub, L. B., and Roth, J. A. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res., 53: 4129-4133, 1993.
59. Bischoff, J., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Wash. DC), 274: 373-376, 1996.
60. Nielsen, L. L., and Maneval, D. C. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther., 5: 52-63, 1998.
61. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-Sorensen, B., Montesano, R., and Harris, C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res., 22: 3551-3555, 1994.
62. Lippman, S. M., Brenner, S. E., and Hong, W. K. The chemoprevention of cancer. In: P. Greenwald, R. S. Kramer, and D. L. Weed (eds.), Cancer Prevention and Control, pp. 329-352. New York: Marcel Dekker, 1995.
63. Lippman, S. M., Shin, D. M., Lee, J. J., Batsakis, J. G., Lotan, R., Tainsky, M. A., Hittleman, W. N., and Hong, W. K. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res., 55: 16-19, 1995.
64. Field, J. K., Spandios, D. A., Stell, P. M., Vaughan, E. D., Evan, G. I., and Moore, J. P. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene, 4: 1463-1469, 1989.
65. Gallick, G. E., Sacks, P. G., Maxwell, S. A., Steck, P. A., and Gutterman, J. U. Head and neck squamous cell carcinoma cell lines as a model system for the study of oncogene expression during tumor progression and metastasis. Prog. Clin. Biol. Res., 212: 97-117, 1986.
66. Tsuda, T., Tahara, E., Kaijyma, G., Sakamoto, M., Tejada, M., and Sugimura, T. High incidence of coamplication of hst-1 and int-2 genes in human esophageal carcinomas. Cancer Res., 49: 5905-5911, 1989.
67. Sozzi, G., Miozzo, M., Donghi, R., Pilotti, S., Cariani, C. T., Pastorino, U. Della Porta, G., and Pierotti, M. A. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res., 52: 6079-6082, 1992.
68. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog. Bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
69. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80: 293-299, 1995.
70. Helene, C., and Toulme, J. J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochem. Biophys. Acta, 1049: 99-125, 1990.
71. Dosaka Akita, H., Akie, K., Hiroumi, H., Kinoshita, I., Kawakami, Y., and Murakami, A. Inhibition of proliferation by L-myc antisense DNA for the translational initiation site in human small cell lung cancer. Cancer Res., 55: 1559-1564, 1995.
72. Robinson, L. A., Smith, L. J., Fontaine, M. P., Kay, H. D., Mountjoy, C. P., and Pirruccello, S. J. c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer. Ann. Thorac. Surg., 60: 1583-1591, 1995.
73. Mukhopadhyay, T., Tainsky, M., Cavender, A. C., and Roth, J. A. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res., 51: 1744-1748, 1991.
74. Lee, C. T., Wu, S., Gabrilovich, D., Chen, H., Nadaf-Rahrov, S., Ciernik, I. F., and Carbone, D. P. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res., 56: 3038-3041, 1996.
75. Deshane, J., Siegal, G. P., Wang, M., Wright, M., Bucy, R. P., Alvarez, R. D., and Curiel, D. T. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy. Gynecol. Oncol., 63: 378-385, 1997.
76. Cochet, O., Kenigsberg, M., Delumeau, I., Virone Oddos, A., Multon, M. C., Fridman, W. H., Schweighoffer, F., Teillaud, J. L., and Tocque, B. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res., 58: 1170-1176, 1998.
77. Cai, W., Mukhopadhyay, T., Liu, Y., Fujiwara, T., and Roth, J. A. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum. Gene Ther., 4: 617-624, 1993.
78. Gavrieli, Y., Sherman, Y., and Ben Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
79. Fujiwara, T., Cai, D. W., Georges, R. N., Mukhopadhyay, T., Grimm, E. A., and Roth, J. A. Therapeutic effect of a retroviral wildtype p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Inst. (Bethesda), 86: 1458-1462, 1994.
80. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen Schaub, L. B., and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
81. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-deficient apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
82. Sandig, V., Brand, K., Herwig, S., Lukas, J., Bartek, J., and Strauss, M. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat. Med., 3: 313-319, 1997.
83. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., and Bartek, J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond.), 375: 503-506, 1995.
84. Kirn, D., Hermiston, T., and McCormick, F. A Phase II trial with an E1B deleted adenovirus, ONXY-015, in patients with recurrent refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol., 17: 1509-1517, 1998.
85. Wildner, O., Blaese, R. M., and Morris, J. C. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of Herpes simplex virus-thymidine kinase. Cancer Res., 59: 410-413, 1999.
86. Hall, A. R., Dix, B. R., O'Carroll, S. J., and Braithwaite, A. W. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat. Med., 4: 1068-1072, 1998.
87. Mitani, K., and Caskey, C. T. Delivering therapeutic genes: matching approach and application. Trends Biotechnol., 11: 162-166, 1993.
88. Goodrum, F. D., and Ornelles, D. A. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol., 72: 9479-9490, 1998.
89. Rothman, T., Hengstermann, A., Whitaker, M., and Hausen, H. Replication of ONXY-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol., 72: 9470-9478, 1998.
90. ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med., 6: 1128-1133, 2000.
91. Yoshimura, K., Rosenfeld, M. A., Seth, P., and Crystal, R. G. Adenovirus-mediated augmentation of cell transfection with unmodified plasmid vectors. J. Biol. Chem., 268: 2300-2303, 1993.
92. Gao, L., Wagner, E., Cotten, M., Agarwal, S., Harris, C., Romer, M., Miller, L., Hu, P. C., and Curiel, D. Direct in vivo gene transfer to airway epithelium employing adenovirus-polylysine-DNA complexes. Hum. Gene Ther., 4: 17-24, 1993.
93. Gottschalk, S., Sparrow, J. T., Hauer, J., Mims, M. P., Leland, F. E., Woo, S. L., and Smith, L. C. A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells. Gene Ther., 3: 48-57, 1996.
94. Wagner, E., Plank, C., Zatloukal, K., Cotton, M., and Birnstiel, M. L. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc. Natl. Acad. Sci. USA, 89: 7934-7938, 1992.
95. Veale, D., Ashcroft, T., Marsh, C., Gibson, G. J., and Harris, A. L. Epidermal growth factor receptors in non-small cell lung cancer. Br. J. Cancer, 55: 513-516, 1987.
96. Cristiano, R. J., and Roth, J. A. Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther., 3: 4-10, 1996.
97. Frederiksen, K. S., Abrahamsen, N., Cristiano, R. J., Damstrup, L., and Poulsen, H. S. Gene delivery by an epidermal growth factor/DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor. Cancer Gene Ther., 7: 262-268, 2000.
98. Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., and Finberg, R. W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (Wash. DC), 275: 1320-1323, 1997.
99. Stevenson, S. C., Rollence, M., White, B., Weaver, L., and McClelland, A. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain, J. Virol., 69: 2850-2857, 1995.
100. Michael, S. I., Huang, C. H., Romer, M. U., Wagner, E., Hu, P. C., and Curiel, D. T. Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway. J. Biol. Chem., 268: 6866-6869, 1993.
101. Foster, B. J., and Kern, J. A. HER2-targeted gene transfer. Hum. Gene Ther., 8: 719-727, 1997.
102. Shimizu, N., Chen, J., Gamou, S., and Takayanagi, A. Immunogene approach toward cancer therapy using epidermal growth factor receptor-mediated gene delivery. Cancer Gene Ther., 3: 113-120, 1996.
103. Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., and Mendelsohn, J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl. Acad. Sci. USA, 80: 1337-1341, 1983.
104. Shinkai, T., Saijo, N., Tominaga, K., Eguchi, K., Shimizu, E., Sasaki, Y., Fujita, J., Futami, H., Ohkura, H., and Suemasu, K. Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy. Cancer (Phila.), 57: 1318-1323, 1986.
105. Schrewe, H., Thompson, J., Bona, M., Hefta, L. J., Maruya, A., Hassauer, M., Shively, J. E., von Kleist, S., and Zimmermann, W. Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression. Mol. Cell. Biol., 10: 2738-2748, 1990.
106. Broers, J. L. V., Jensen, S. M., Travis, W. D., Pass, H., Whitsett, J. A., Singh, G., Katyal, S. L., Gazdar, A. F., Minna, J. D., and Linnoila, R. I. Expression of surfactant associated protein-A and Clara cell 10 kiladalton mRNA in neoplastic and non-neoplastic human lung tissue as detected by in situ hybridization. Lab. Investig., 66: 337-346, 1992.
107. Gu, J., Kagawa, S., Takakura, M., Kyo, S., Inoue, M., Roth, J. A., and Fang, B. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res., 60: 5359-5364, 2000.
108. Smith, M. J., Rousculp, M. D., Goldsmith, K. T., Curiel, D. T., and Garver, R. I., Jr. Surfactant protein A-directed toxin gene kills lung cancer cells in vitro. Hum. Gene Ther., 5: 29-35, 1994.
109. Blackwood, E. M., and Kadonaga, J. T. Going the distance: a current view of enhancer action. Science (Wash. DC), 281: 61-63, 1998.
110. Eisenberg, S. P., Coen, D. M., and McKnight, S. L. Promoter domains required for expression of plasmid-borne copies of the herpes simplex virus thymidine kinase gene in virus-infected mouse fibroblasts and microinjected frog oocytes. Mol. Cell. Biol., 5: 1940-1947, 1985.
111. Roth, J. A., Swisher, S. C., Merritt, J. A., Lawrence, D. D., Kemp, B. L., Carrasco, C. L., El-Naggar, A. K., Fossella, F. V., Glisson, B. S., Hong, W. K., Khurl, F. R., Kurie, J. M., Nesbitt, J. C., Pisters, K., Putnam, J. B., Schrump, D. S., Shin, D. M., and Walsh, G. L. Gene therapy for non-small cell lung cancer: a preliminary report of a Phase I trial of adenoviral p53 gene replacement. Semin. Oncol., 25: 33-37, 1998.
112. Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Connors, D. G., El-Naggar, A. K., Fossella, F., Glisson, B. S., Hong, W. K., Khuri, F. R., Kurie, J. M., Lee, J. J., Lee, J. S., Mack, M., Merritt, J. A., Nguyen, D. M., Nesbitt, J. C., Perez-Soler, R., Pisters, K. M., Putnam, J. B., Richli, W. R., Savin, M., Schrump, D. S., Shin, D. M., Shulkin, A., Walsh, G. L., Wait, J., Wiell, D., and Waugh, M. K. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (Bethesda), 91: 763-771, 1999.
113. Nemunaitis, J., Swisher, S. G., Timmons, T., Connors, D., Mack, M., Doerksen, L., Weill, D., Wait, J., Lawrence, D. D., Kemp, B. L., Fossella, F., Glisson, B. S., Hong, W. K., Khuri, F. R., Kurie, J. M., Lee, J. J., Lee, J. S., Nguyen, D. M., Nesbitt, J. C., Perez-Soler, R., Pisters, K. M., Putnam, J. B., Richli, W. R., Shin, D. M., Walsh, G. L., Merritt, J., and Roth, J. A. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. J. Clin. Oncol., 18: 609-622, 2000.
114. Schuler, M., Herrmann, R., De Greve, J., Stewart, A. K., Gatzemeier, U., Stewart, D., Laufman, L., Gralla, R., Kuball, J., Buhl, R., Heussel, C. P., Kommoss, F., Perruchoud, A. P., Shepherd, F. A., Fritz, M. A., Horowitz, J. A., Huber, C., and Rochlitz, C. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter Phase II study. J. Clin. Oncol., 19: 1750-1758, 2001.
115. Swisher, S. G., Roth, J. A., Komaki, R., Gu, J., Lee, J. J., Hicks, M., Ro, J. Y., Hong, W. K., Merritt, J. A., Ahrar, K., Atkinson, N. E., Correa, A. M., Dolormente, M., Dreiling, L., El-Naggar, A. K., Fossella, F., Francisco, R., Glisson, B., Grammer, S., Herbst, R., Huaringa, A., Kemp, B., Khuri, F. R., Kurie, J. M., Liao, Z., McDonnell, T. J., Morice, R., Morello, F., Munden, R., Papadimitrakopoulou, V., Pisters, K. M., Putnam, J. B., Jr., Sarabia, A. J., Shelton, T., Stevens, C., Shin, D. M., Smythe, W. R., Vaporciyan, A. A., Walsh, G. L., and Yin, M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res., 9: 93-101, 2002.
116. Le Chevalier, T., Arriagada, R., Quoix, E., Ruffie, P., Martin, M., Tarayre, M., Lacombe-Terrier, M. J., Douillard, J. Y., and Laplanche, A. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J. Natl. Cancer Inst. (Bethesda), 83: 417-423, 1991.
117. Kubba, S., Adak, S., Schiller, J., Slovis, B., Coffee, K., Worrell, J., et al. Phase I trial of adenovirus p53 in bronchioloalveolar cell lung carcinoma (BAC) administered by bronchoalveolar lavage. Proc. Am. Soc. Clin. Oncol., 19: 487a, 2000.
118. Clayman, G. I., el-Nager, A. K., Lippman, S. M., Henderson, Y. C., Fredrick, M., Merritt, J. A., Zumstein, L. A., Timmons, T. M., Liu, T. J., Ginsberg, L., Roth, J. A., Hong, W. K., Bruso, P., and Goepfert, H. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol., 16: 2221-2232, 1998.
119. Goodwin, W. J., Esser, D., Clayman, G., Nemunaitis, J., Yver, A., Dreiling, L., et al. Randomized Phase II study of intratumoral injection of two dosing schedules using a replication-deficieint adenovirus carrying the P53 gene (AD5CMV-P53) in patient with recurrent/refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol., 18: 445a, 1999.
120. Bier-Laning, C., Van Echo, D., Yver, A., and Dreiling, L. A. Phase II multi-center study of AD5CMV-P53 administered intratumorally to patients with recurrent head and neck cancer. Proc. Am. Soc. Clin. Oncol., 18: 444a, 1999.
121. Yver, A., Dreiling, L., Mohanty, S., Merritt, J., Proksch, S., Shu, C., et al. Tolerance and safety of RPR/INGN 201, an adeno-viral vector containing a p53 gene, administered intratumorally in 309 patients with advanced cancer enrolled in Phase I and II studies world-wide. Proc. Am. Soc. Clin. Oncol., 19: 460a, 2000.
122. Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., Romel, L., Randlev, B., Kaye, S., and Kirn, D. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol., 19: 289-298, 2001.
123. Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Randlev, B., Reid, T., Kaye, S., and Kirn, D. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 6: 879-885, 2000.
124. Hecht, J. R., Bedford, R., Abbruzzese, J. L., Lahoti, S., Reid, T. R., Soetikno, R. M., Kirn, D. H., and Freeman, S. M. A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res., 9: 555-561, 2003.
125. Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Wein, L. M., Andrews, J., Randlev, B., Heise, C., Uprichard, M., Hatfield, M., Rome, L., Rubin, J., and Kirn, D. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res., 62: 6070-6079, 2002.